ACER Acer Therapeutics Inc.

19.78
-2.93  -13%
Previous Close 22.71
Open 22.98
Price To Book 4.42
Market Cap 199528040
Shares 10,087,363
Volume 101,148
Short Ratio
Av. Daily Volume 39,036

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date under priority review June 25, 2019.
EDSIVO
Vascular Ehlers-Danlos Syndrome
Phase 2b trial did not meet primary endpoint - October 28, 2016.
Tovaxin (Tcelna)
Secondary Progressive MS (SPMS)
NDA filing planned for 2019.
ACER-001
Urea cycle disorder (UCD)